Buy Champix tablets with our Product Satisfaction Guarantee
Champix and Varenicline drugs contain the same active substance
One of the most effective medical benefits of Champix (Varenicline) is smoking cessation in the patients. During quantitative statistical analysis in 2009, it was observed that Varenicline is more effective than bupropion and nicotine replacement therapies.
Moreover, in 2013 another quantitative statistical analysis proved that Varenicline is 3 times more powerful treatment for the chronic patients of smoking than the other medications. It has justified its medical capabilities for tobacco cessation. Bupropion and nicotine replacement therapies or combination of both are still less effective as that of Champix alone.
Varenicline can be used for 3 months as approved by the Food and Drug Administration (FDA) of the USA. If patient shows positive effects over Varenicline, then the treatment can be prolonged for smoking cessation with prescription of Champix tablet for 3 more months.
Champix is the trade name of Varenicline. Varenicline is a medicine used during the treatment of patients addicted to nicotine containing products. This drug has tendency to minimize the attraction of patients towards the nicotine containing products and reduce the pleasurable feelings from nicotine.
It has ability to make release of dopamine in the active nucleus of accumben. Consequently, Varenicline has property to minimize the attraction of patient towards nicotine containing products. Moreover, it is concluded that Varenicline functions just like nicotine patches and nicotine gum. Champix pills has similar properties of cytisine while much different characteristics of the nicotine replacement therapies and nicotinic antagonist bupropion.
Due to concerns associated with the safety and its prominent clinical effectiveness along with experience, the US FDA expressed priority review about Varenicline in 2006. It causes to reduce the scheduled review time period of 10 months to 6 months. In 2006, both the United States and European Union approved the sale of Champix.
The effects of Varenicline on women during pregnancy and under the age of 18 years old have not yet been observed experimentally. So, Champix pill is not favored to prescribe this category of patients. It has been tested on animals, and during these tests there were no abnormalities or risk towards their pregnancy, as no experimental results are yet available for human beings. Consequently, Varenicline is a class C pregnancy medicine. Moreover, an experimental study is in progress to document the abnormalities and irregularities caused by Varenicline, but there are no results yet.
Based on the animal's observation, alternate medications are preferred for breastfeeding patients to stop the smoking and nicotine containing products.
It is observed that there are no harmful effects of Varenicline dosage for cardiovascular patients and self-harm or depression patients. The experimental observation showed that there is no risk of enhanced rate of suicide among consumers of the drug. Even with extended survey among patients, it is claimed that there is no risk of neuropsychiatric side effects with the intake of Varenicline supplement.
It is imperative to mention that patients taking dose of Champix drugs are still advised not to use the medication if any side effect is observed including change of thinking, mood swings and depression. So be very careful with doses.
Patients taking Varenicline as a regular supplement for smoking cessation feel slight nausea. Nausea is observed in approximately 30% of Champix tablets consumers, consequently less than 3% of patients quite taking supplements of the drug. Varenicline also possess side effects including nightmares, headache and sleeping difficulty. Other side effects caused by regular supplements of Varenicline include constipation, abdominal pain, vomiting and flatulence. Moreover, it has been claimed that the patients taking regular supplement of Varenicline feel different issues. These may include a patient having flatulence in 35 treated patients and a constipation patient in 24 subjects. Nausea is also very common in every five subjects treated with Varenicline. It also has some side effects over gastrointestinal tract which may lead the discontinuation of dosage to the patients. Those patients taking higher supplement of Champix drug are more prone to face nausea as compared to the patients with less dosage.
Varenicline shows proper counteracting action on a7 nicotinic acetylcholine receptors. Moreover, Varenicline also show partial counteraction on a3b4, a4b2, and a6b2 subtypes. It is imperative to mention that it is a weak agonist on the a3b2 containing receptors.
As it is observed that the Varenicline has partial agonism on the a4b2 receptors and possess full agonism over nicotine, consequently, it gives less effect of dopamine release than nicotine does. As in the treatment of opioid addiction by buprenorphine, a a4b2 binding force minimizes and reduces the capability of nicotine to arouse the mesolimbic dopamine system.
92 to 93 percent of active compounds from human body are excreted from kidney. These include percentages of hexose, glucuronidated and oxidized.